Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

OTS-11101 is well tolerated in first-in-human study in solid tumors

June 14, 2011

GQ-16 may provide safe PPAR-gamma activation for diabetes treatment

June 10, 2011

Phase I trial assesses safety and tolerability of KW-2450 in pretreated advanced solid tumors

June 10, 2011

Galapagos discloses first-in-human data on GLPG-0634

June 10, 2011

Sirukumab is safe in patients with rheumatoid arthritis, cutaneous and systemic lupus erythematosus

June 10, 2011

Hyaluronic acid as a biomarker of lung cancer diagnosis and prognosis

June 9, 2011

New clinical data presented on lurasidone in schizophrenia

June 9, 2011

LGD-4033 well tolerated in healthy volunteers at multiple doses

June 9, 2011

Yokukansan reduces delirium after acute ischemic stroke

June 9, 2011

Interim data from first-in-human trial of Pfizer's CVX-241 support safety in advanced solid tumors

June 9, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 28, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...